Clinical trial track DAVA Oncology specializes in accelerating patient recruitment and retention for cancer clinical trials, with a history of over 45 Phase I-III trials and an average accrual enhancement rate of 30-40% in the last six years. This indicates strong value proposition for sponsors seeking faster trial enrollment and higher data integrity.

Oncology ecosystem Their ONE Oncology initiative aims to improve drug development understanding and decision-making through consolidating and disseminating cancer knowledge, complemented by Oncology Meeting Innovations that connect academic and community oncologists. This positions DAVA as a bridge for sponsor networks to access diverse investigative sites.

Tech Enablement DAVA leverages a modern tech stack including WordPress, Zoho, Google Cloud, and Claude by Anthropic, suggesting opportunities to offer integrated digital patient engagement, CRM optimization, and data-driven trial analytics services to optimize study operations.

Growth & risk With an estimated revenue range of 10 to 25 million and a relatively small team (11-50 employees), DAVA presents a scalable services model for mid-market sponsors and CROs seeking specialized trial recruitment capabilities, though recent securities litigation news may require due diligence in client onboarding and reputation management.

Partnership potential Given the focus on oncology knowledge dissemination and physician-focused recruitment, there are cross-sell opportunities with larger CROs or biopharma sponsors looking to augment patient enrollment, site coordination, and data-sharing capabilities within an oncology-focused ecosystem.